BEST UNLIMITED TURBO LONG CERTIFICATE - NOVO-NORDISK B | Market Closed - Euronext Paris 10:00:01 10/05/2024 pm IST | ||
| 26.48 EUR | +0.98% |
|
| Current month | -0.38% | ||
| 1 month | +5.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 26.57 | +1.34% | 95 |
| 09/24/09 | 26.22 | +0.48% | 100 |
| 08/24/08 | 26.1 | +0.75% | 115 |
| 07/24/07 | 25.9 | +5.66% | 120 |
| 06/24/06 | 24.52 | +0.90% | 113 |
Real-time Euronext Paris
Last update May 10, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| SN26S | |
| ISIN | DE000SQ3UKM5 |
| Date issued | 04/11/2022 |
| Strike | 400.3 kr |
| Maturity | Unlimited |
| Parity | 2.5 : 1 |
| Emission price | 3.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.85 € |
|---|---|
| Lowest since issue | 1.857 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- SN26S Certificat